Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
IRWD
)
5.390
+0.080 (+1.51%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Top 4 Health Care Stocks You May Want To Dump In February
↗
February 15, 2024
As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
February 15, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For February 15, 2024
↗
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
A Preview Of Ironwood Pharmaceuticals's Earnings
↗
February 14, 2024
Via
Benzinga
Chart Of The Day: Ironwood Pharma - Gastrointestinal Products
↗
February 13, 2024
Via
Talk Markets
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
February 01, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Earnings Preview For Ironwood Pharmaceuticals
↗
August 07, 2023
Via
Benzinga
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
January 08, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
January 08, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
December 12, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
November 30, 2023
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...
Via
Newsfile
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
November 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
October 26, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
October 23, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
October 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
October 05, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 19, 2023
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
↗
September 28, 2023
Via
Benzinga
Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday
↗
September 19, 2023
U.S. stocks traded lower on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
August 08, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
July 25, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
June 29, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
June 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
June 12, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
↗
June 12, 2023
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.
Via
The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
↗
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
↗
May 22, 2023
Investors indicated approval of the company's upcoming $1 billion asset purchase.
Via
The Motley Fool
Ironwood Scoops Up Gastrointestinal Diseases Player For $1B
↗
May 22, 2023
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has agreed to acquire VectivBio Holding AG (NASDAQ: VECT) for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
